{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LPV%2Fr", "query": { "intervention": "LPV/r" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LPV%2Fr&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T05:26:30.199Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00708162", "title": "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Elvitegravir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "EVG placebo", "type": "DRUG" }, { "name": "RAL placebo", "type": "DRUG" }, { "name": "Background regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 724, "start_date": "2008-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-30", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 94, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00708162" }, { "nct_id": "NCT00084149", "title": "Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate, Lamivudine, and Zidovudine", "type": "DRUG" }, { "name": "Lopinavir/Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2004-02", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 4, "location_summary": "Minneapolis, Minnesota • New York, New York • Cleveland, Ohio", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084149" }, { "nct_id": "NCT02140255", "title": "Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Nevirapine (NVP)", "type": "DRUG" }, { "name": "Lopinavir/Ritonavir (LPV/r)", "type": "DRUG" }, { "name": "Raltegravir (RAL)", "type": "DRUG" }, { "name": "VRC01", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "48 Hours", "sex": "ALL", "summary": "Up to 48 Hours" }, "enrollment_count": 1120, "start_date": "2015-01-23", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 21, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02140255" }, { "nct_id": "NCT00414284", "title": "BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Increased dose of Kaletra", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Community Research Initiative of New England", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2006-06", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2010-12-08", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00414284" }, { "nct_id": "NCT00756730", "title": "Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ATV/r", "type": "DRUG" }, { "name": "DRV/r", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Community Research Initiative of New England", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2008-09", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2017-08-21", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00756730" }, { "nct_id": "NCT01172535", "title": "A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Lopinavir/ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": null, "sex": "ALL", "summary": "4 Weeks and older" }, "enrollment_count": 97, "start_date": "2010-11", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 3, "location_summary": "La Jolla, California • Aurora, Colorado • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01172535" }, { "nct_id": "NCT00474201", "title": "Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Lopinavir/Ritonavir", "type": "DRUG" }, { "name": "Gemfibrozil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2007-05", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2016-09-26", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474201" }, { "nct_id": "NCT02121795", "title": "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/TDF", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "Allowed third antiretroviral agent", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 668, "start_date": "2014-05-06", "completion_date": "2019-03-01", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02121795" }, { "nct_id": "NCT00752856", "title": "Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Kaletra + Isentress", "type": "DRUG" }, { "name": "Atripla", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2008-08-26", "completion_date": "2014-02-11", "has_results": true, "last_update_posted_date": "2020-07-22", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 6, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 3 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752856" }, { "nct_id": "NCT00023218", "title": "Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Lopinavir/Ritonavir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-09", "last_synced_at": "2026-09-10T05:26:30.199Z", "location_count": 3, "location_summary": "Honolulu, Hawaii • Tripler AMC, Hawaii • New York, New York", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "Tripler AMC", "state": "Hawaii" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023218" } ] }